Saturday 17 October 2026
Export MBIO’s income statement to Excel — free account
Mustang Bio, Inc.
MBIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 15.8% and free cash flow grew 27.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.38
0.01
−2.56%
Follow MBIO
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 6,041.25 | 1,635.00 | 1,882.50 | 1,335.00 | 1,215.00 | 236.25 | 60.50 | 6.40 | 0.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | 10,012.50 | 9,667.50 | 7,650.00 | 3,637.50 | 3,915.00 | 1,376.25 | 554.25 | 76.50 | 21.95 | |||||
| People | |||||||||||||||
| People | Employees | 3 | 6 | 38 | 51 | 62 | 102 | 113 | 80 | 6 | 4 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (13) | (31) | (31) | (46) | (60) | (66) | (78) | (52) | (16) | (2) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (13) | (31) | (31) | (46) | (60) | (66) | (78) | (52) | (16) | (2) | |||||
| Depreciation | 1 | 0 | 1 | 2 | 4 | 2 | 4 | 2 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (860.23) | (929.53) | (854.57) | (967.02) | (854.57) | (569.71) | (562.22) | (300.00) | (25.82) | (0.39) | |||||
| Cash flow | (280.88) | (384.21) | (536.04) | (698.15) | (531.61) | (457.91) | (423.33) | (287.66) | (18.70) | (1.07) | |||||
| Capex | 0.00 | (83.06) | (221.31) | (76.82) | (62.85) | (45.78) | (19.21) | 34.22 | 0.00 | 0.24 | |||||
| Free cash flow | (280.88) | (467.27) | (757.35) | (774.97) | (594.46) | (503.69) | (442.54) | (253.44) | (18.70) | (0.84) | |||||
| Book value | 1,651.43 | 1,775.43 | 1,013.82 | 1,073.85 | 1,402.21 | 959.04 | 301.06 | 0.72 | (6.35) | 1.94 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (4) | (13) | (19) | (34) | (37) | (54) | (65) | (49) | (11) | (5) | ||||
| Capex | — | (3) | (8) | (4) | (4) | (5) | (3) | 6 | 0 | 1 | |||||
| Free cash flow | (4) | (16) | (27) | (37) | (42) | (59) | (68) | (44) | (11) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 24 | 58 | 30 | 55 | 90 | 101 | 64 | (4) | (4) | 10 | ||||
| Total debt | 0 | — | — | 13 | 2 | 2 | 27 | — | — | — | |||||
| Net debt | (27) | (61) | (34) | (48) | (96) | (108) | (48) | (6) | (7) | (17) | |||||
| Shareholders’ equity | 24 | 60 | 36 | 52 | 98 | 112 | 46 | 0 | (4) | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (92.03) | (68.77) | (57.72) | (79.84) | (65.47) | (56.47) | (71.26) | (93.68) | (116.47) | (14.28) | ||||
| ROIC | 0.00 | 0.00 | (840.05) | (781.85) | (1,375.58) | (933.55) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (125.62) | (74.40) | (63.73) | (105.37) | (79.97) | (62.96) | (97.72) | (222.44) | 840.11 | (67.93) | |||||
Negative figures in brackets.
Charts ten years each
Mustang Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARAV ARAVIVE, INC | $3.0M | — (loss-making) | — (loss-making) | −44.39% (below 0%: shrinking) | n/m | +48.19% (above 0%: growing) | 100.00% | (323.44%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.9M | 0.0× | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| MBIO Mustang Bio, Inc. | $2.9M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| ONCO Onconetix, Inc. | $2.9M | 0.0× | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| VIVS VivoSim Labs, Inc. | $2.8M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| Median of peers | $2.9M | 0.0× | — | −47.87% | — | +20.49% | 62.58% | (161.72%) |
Mustang Bio, Inc. (MBIO) key facts
- Mustang Bio, Inc. (MBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MBIO traded at $0.38, a market capitalization of $2.9 million.
- Return on equity was −67.9% and debt-to-equity 0.00.
Mustang Bio, Inc. (MBIO) Latest News
No news at this impact. Lower the threshold for more.